Related Experiment Video
Updated: Aug 5, 2026
09:01
The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents
Published on: July 8, 2015
Beyond memory impairment: cognitive changes in Alzheimer's disease
1Department of Psychology, University of Western Ontario, London, ON, Canada. e.helmes@cowan.edu.au
Summary
Alzheimer's disease (AD) involves more than memory loss, affecting language and motor skills. Cognitive deficits worsen with AD severity, but current tests don't differentiate diagnostic levels.
Area of Science:
- Neurology
- Gerontology
- Cognitive Science
Background:
- Alzheimer's disease (AD) diagnosis primarily focuses on memory impairment.
- Advanced AD stages often present with broader cognitive deficits beyond memory loss.
Purpose of the Study:
- To determine the prevalence of non-memory cognitive deficits in Alzheimer's disease.
- To compare cognitive performance between AD patients and cognitively healthy controls.
Main Methods:
- A large, representative sample of elderly Canadians (749 with AD, 563 controls) was analyzed.
- Neuropsychological tests assessed aphasia, apraxia, agnosia, and other cognitive functions.
Main Results:
- Deficits in complex visuomotor tasks, abstract thinking, aphasia, and constructional abilities were more common than agnosia.
- Symptom prevalence increased and neuropsychological test performance decreased with AD severity.
- Diagnostic categories of 'possible' and 'probable' AD showed similar performance levels.
Conclusions:
- Alzheimer's disease impacts multiple cognitive domains, not just memory.
- The distinction between 'possible' and 'probable' AD may not be clinically significant based on current testing.
- Further research is needed to refine diagnostic criteria and understand the full spectrum of AD-related cognitive decline.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...